Connecticut will net more than $10 million of a $2.2 billion global settlement with pharmaceutical and consumer products giant Johnson & Johnson over alleged illegal drug marketing practices and doctor kickbacks, state officials announced.
The settlement, which involves the federal government and several states, settles allegations that Johnson & Johnson and its subsidiary Janssen Pharmaceuticals marketed two antipsychotic drugs — Risperdal and Invega — for uses not approved by the U.S. Food and Drug Administration.
Janssen will also plead guilty in federal court to a criminal misdemeanor charge of misbranding Risperdal.
The companies were also accused of making false and misleading statements about the drugs to doctors and pharmacy providers and providing illegal kickbacks to doctors to prescribe the drugs. The alleged behavior happened between 1999 and 2005 and between 2007 and 2009, officials said.
Nearly all of the settlement, $1.1 billion, will go to state Medicaid programs, including Connecticut’s.
